Prognostic Accuracy of DSM-5 Attenuated Psychosis Syndrome in Adolescents: Prospective Real-World 5-Year Cohort Study

• Published in: Schizophrenia bulletin 2021-10, Vol.47 (6), p.1663-1673
• Main Authors: Mensi, Martina Maria, Molteni, Silvia, Iorio, Melanie, Filosi, Eleonora, Ballante, Elena, Balottin, Umberto, Fusar-Poli, Paolo, Borgatti, Renato
• Format: Article
• Language: English
• Subjects: Adolescent; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disease Progression; Female; Humans; Italy - epidemiology; Male; Patient Acceptance of Health Care; Prodromal Symptoms; Prognosis; Prospective Studies; Psychotic Disorders - diagnosis; Psychotic Disorders - epidemiology; Psychotic Disorders - therapy; Regular; Risk; Schizophrenia - diagnosis; Schizophrenia - epidemiology; Schizophrenia - therapy; Sensitivity and Specificity; Syndrome
• ISSN: 0586-7614; 1745-1701
• DOI: 10.1093/schbul/sbab041

Abstract There is limited research in adolescents at risk for psychosis. The new Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition attenuated psychosis syndrome (DSM-5 APS) criteria have not been validated in this group. We conducted a RECORD-compliant, real-world, prospective, 5-year cohort study addressing clinical profile, transition to psychosis, and prognostic accuracy of DSM-5 APS in help-seeking inpatient/outpatient adolescents accessing Children and Adolescent Neuropsychiatric services at IRCCS Mondino Foundation (Pavia, Lombardy, Italy) between 2012 and 2019. About 243 adolescents (31 early-onset psychosis [EOP]; 110 meeting DSM-5 APS criteria, DSM-5 APS; 102 not meeting psychotic or DSM-5 APS criteria, non-APS) were included. At baseline, DSM-5 APS adolescents (aged 15.4 ± 1.6) had on average 2.3 comorbid disorders (higher than EOP/non-APS, P < .001). DSM-5 APS adolescents had an intermediate psychopathological profile between non-APS/EOP (P < .001) and worsen Clinical Global Impression-Severity than non-APS (P < .001). DSM-5 APS functioning was intermediate between non-APS and EOP. 39.1% of DSM-5 APS were treated with psychotropic drugs (average = 64 days); 53.6% received psychotherapy. Follow-up of DSM-5 APS and non-APS groups lasted 33 and 26 months, respectively (median). The cumulative risk of transition at 1–5 years was 13%, 17%, 24.2%, 26.8%, and 26.8% in the DSM-5 APS group, 0%, 0%, 3.2%, 3.2%, and 3.2% in the non-APS group. The 5-year prognostic accuracy of the DSM-5 APS in adolescent was adequate (area under the curve = 0.77; Harrell’s C = 0.736, 95%CI 0.697–0.775), with high sensitivity (91.3%) and suboptimal specificity (63.2%). The DSM-5 APS diagnosis can be used to detect help-seeking adolescents at risk of psychosis and predict their long-term outcomes. Future research should consolidate these findings.